Roche signed a new collaboration with C4 Therapeutics to develop degrader-antibody conjugates (DACs), combining Roche ADC delivery experience with C4’s targeted protein degradation payload platform. Roche committed an upfront payment alongside more than $1 billion in potential discovery, development, regulatory, and commercial milestones. Under the agreement, the partners will identify and design antibodies against two undisclosed oncology targets, then fuse them with C4’s degrader payloads using C4’s platform approach. The collaboration also includes an option to add a third target. The DAC concept seeks to merge antibody targeting with catalytic degradation to widen therapeutic windows and address resistance issues seen with conventional payload delivery strategies. The pact reinforces that protein degradation is evolving from a standalone modality into integrated hybrid formats, pushing Big Pharma toward next-generation constructs that attempt to control both targeting and downstream protein removal.